Remove 2006 Remove Marketing Remove Regulations
article thumbnail

Analyzing biosimilar market dynamics in different patient populations

Drug Patent Watch

As we delve into the intricate world of biosimilar market dynamics, we’ll explore how these complex molecules are reshaping treatment paradigms across diverse patient populations. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 from 2020 to 2025[1].

article thumbnail

PBM Industry Update: Trends, Challenges, and What's Ahead (NEW Live Video Webinar)

Drug Channels

Fein will provide invaluable insights to help you and your team stay informed about this rapidly evolving market. 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Emerging controversies, challenges, and threats to watch in the industry And much more! Unfortunately, we are unable to offer refunds.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What’s Next for Retail Pharmacy: Data, Debate, and Disruption (NEW Live Video Webinar)

Drug Channels

Adam and Antonio will share their unique insights on the pharmacy market and engage in a dynamic, real-time debate you wont want to miss! 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. DCI reserves the right to prohibit purchasers who violate our terms from attending future DCI webinars.

article thumbnail

The Booming Biosimilar Market of 2020

Drug Channels

The biosimilar market is finally beginning to fulfill its promise. What’s more, manufacturers of reference products are cutting drug prices to defend their market shares. What’s more, manufacturers of reference products are cutting drug prices to defend their market shares. As you will see below, Dr. Gottlieb was right.

article thumbnail

The Booming Biosimilar Market of 2020 (rerun)

Drug Channels

The biosimilar market is finally beginning to fulfill its promise. What’s more, manufacturers of reference products are cutting drug prices to defend their market shares. Last year, Dr. Scott Gottlieb, a former FDA commissioner, argued that we shouldn’t give up on biosimilars and prematurely regulate prices.

article thumbnail

How and Why I Was Overcharged by Penn Medicine and My Blue Cross Health Plan (A True Story)

Drug Channels

This tale neatly summarizes why so many people hate our healthcare system—and why the average patient will have trouble benefiting from transparency regulations. Read more » Copyright © 2006-2021 Pembroke Consulting, Inc. to 1:30 p.m. CLICK HERE TO LEARN MORE AND SIGN UP. d/b/a Drug Channels Institute.

article thumbnail

Available for Preorder: The 2023 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

Pharmacies and Pharmacy Benefit Managers is a definitive, nonpartisan resource that includes the most current information about pharmacy dispensing channels, third-party payers, pharmacy benefit managers (PBMs), patients’ financial contributions, government regulations, and much more. Copyright © 2006-2023 Pembroke Consulting, Inc.